Across TCGA pan-cancer cohorts, C10orf53 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C10orf53 data layer compared with 18 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher C10orf53 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C10orf53 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
BRCA, ESCA, and UCEC are the cancer types where C10orf53 Mutation most reproducibly stratifies survival.